Références
Yuki N, Hartung HP (2012) Guillain-Barré syndrome. New Engl J Med 366:2294–304
Willison, HJ, Jacobs BC, van Doorn, PA (2016) Guillain-Barré syndrome. Lancet (doi:10.1016/S0140-6736(16)00339-1)
van Doorn PA (2013) Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). Presse Med 42:193–201
Ruts L, Drenthen J, Jacobs BC, et al (2010) Distinguishing acuteonset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology 74:1680–6
Visser LH, van der Meché FG, Meulstee J, van Doorn PA (1998) Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. J Neurol Neurosurg Psychiatr 64:242–4
Hughes RAC, Swan AV, van Doorn PA (2014) Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 9:CD002063
Osterman PO, Fagius J, Säfwenberg J, Wikström B (1988) Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with plasma exchange. Acta Neurol Scand 77:273–7
Kleyweg, RP, van der Meché FG (1991) Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatr 54:957–60
Ansar V, Valadi N (2015) Guillain-Barré syndrome. Prim Care 42:189–93
Dourado ME, De Freitas ML, Dos Santos FM (1998) Fluctuations in Guillain-Barré syndrome related with intravenous human immunoglobulin (triphasic course): case report. Arq Neuropsiquiatr 56:476–9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Isnard, M., Sauvajon, D., Miret, N. et al. Rechute précoce du syndrome de Guillain-Barré sévère traité par immunoglobulines intraveineuses. Diagnostic et prise en charge. Réanimation 25 (Suppl 4), 194–196 (2016). https://doi.org/10.1007/s13546-016-1205-4
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13546-016-1205-4